# Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

> **NCT00826449** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Lung Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00826449
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2016-06-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826449, "Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00826449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*